UBS Group’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $155M | Sell |
713,200
-273,800
| -28% | -$60.7M | 0.02% | 749 |
|
|
2025
Q4 | $226M | Buy |
987,000
+228,300
| +30% | +$52M | 0.04% | 521 |
|
|
2025
Q3 | $176M | Buy |
758,700
+135,500
| +22% | +$27.6M | 0.03% | 654 |
|
|
2025
Q2 | $116M | Sell |
623,200
-281,800
| -31% | -$52.4M | 0.02% | 860 |
|
|
2025
Q1 | $190M | Sell |
905,000
-188,600
| -17% | -$36.7M | 0.03% | 533 |
|
|
2024
Q4 | $194M | Sell |
1,093,600
-156,800
| -13% | -$28.8M | 0.04% | 524 |
|
|
2024
Q3 | $247M | Buy |
1,250,400
+182,200
| +17% | +$34M | 0.05% | 326 |
|
|
2024
Q2 | $183M | Sell |
1,068,200
-419,100
| -28% | -$69.4M | 0.05% | 377 |
|
|
2024
Q1 | $271M | Sell |
1,487,300
-256,648
| -15% | -$44.2M | 0.07% | 281 |
|
|
2023
Q4 | $270M | Buy |
1,743,948
+364,948
| +26% | +$53.2M | 0.08% | 239 |
|
|
2023
Q3 | $206M | Buy |
1,379,000
+397,500
| +40% | +$58.4M | 0.07% | 282 |
|
|
2023
Q2 | $132M | Sell |
981,500
-57,800
| -6% | -$8.48M | 0.04% | 401 |
|
|
2023
Q1 | $166M | Sell |
1,039,300
-401,500
| -28% | -$61.4M | 0.06% | 315 |
|
|
2022
Q4 | $233M | Buy |
1,440,800
+197,100
| +16% | +$30.2M | 0.09% | 240 |
|
|
2022
Q3 | $167M | Sell |
1,243,700
-67,400
| -5% | -$9.67M | 0.07% | 276 |
|
|
2022
Q2 | $201M | Sell |
1,311,100
-153,200
| -10% | -$23.4M | 0.08% | 258 |
|
|
2022
Q1 | $237M | Sell |
1,464,300
-1,116,174
| -43% | -$162M | 0.08% | 257 |
|
|
2021
Q4 | $349M | Buy |
2,580,474
+920,338
| +55% | +$109M | 0.1% | 203 |
|
|
2021
Q3 | $179M | Buy |
1,660,136
+272,800
| +20% | +$31.2M | 0.06% | 331 |
|
|
2021
Q2 | $156M | Buy |
1,387,336
+330,613
| +31% | +$37.2M | 0.05% | 370 |
|
|
2021
Q1 | $114M | Sell |
1,056,723
-383,879
| -27% | -$41.1M | 0.04% | 456 |
|
|
2020
Q4 | $154M | Buy |
1,440,602
+258,821
| +22% | +$24.9M | 0.05% | 344 |
|
|
2020
Q3 | $104M | Sell |
1,181,781
-145,418
| -11% | -$13.7M | 0.04% | 385 |
|
|
2020
Q2 | $130M | Sell |
1,327,199
-515,101
| -28% | -$45.4M | 0.06% | 314 |
|
|
2020
Q1 | $140M | Buy |
1,842,300
+284,200
| +18% | +$24.2M | 0.07% | 269 |
|
|
2019
Q4 | $138M | Buy |
1,558,100
+593,000
| +61% | +$49.2M | 0.05% | 348 |
|
|
2019
Q3 | $73.1M | Buy |
965,100
+471,700
| +96% | +$32.3M | 0.03% | 521 |
|
|
2019
Q2 | $35.9M | Sell |
493,400
-900,100
| -65% | -$70.7M | 0.01% | 852 |
|
|
2019
Q1 | $112M | Buy |
1,393,500
+1,056,600
| +314% | +$86.4M | 0.05% | 361 |
|
|
2018
Q4 | $31.1M | Sell |
336,900
-10,000
| -3% | -$879K | 0.01% | 824 |
|
|
2018
Q3 | $32.8M | Buy |
346,900
+34,500
| +11% | +$3.27M | 0.01% | 890 |
|
|
2018
Q2 | $28.9M | Sell |
312,400
-22,000
| -7% | -$2.15M | 0.01% | 949 |
|
|
2018
Q1 | $31.7M | Sell |
334,400
-209,600
| -39% | -$23M | 0.01% | 862 |
|
|
2017
Q4 | $52.6M | Buy |
544,000
+33,900
| +7% | +$3.19M | 0.02% | 645 |
|
|
2017
Q3 | $45.3M | Sell |
510,100
-11,500
| -2% | -$875K | 0.02% | 641 |
|
|
2017
Q2 | $37.8M | Sell |
521,600
-194,600
| -27% | -$13.1M | 0.02% | 701 |
|
|
2017
Q1 | $46.7M | Sell |
716,200
-48,100
| -6% | -$3.02M | 0.03% | 576 |
|
|
2016
Q4 | $47.9M | Buy |
764,300
+148,100
| +24% | +$9.04M | 0.03% | 568 |
|
|
2016
Q3 | $38.9M | Buy |
616,200
+4,500
| +0.7% | +$291K | 0.02% | 624 |
|
|
2016
Q2 | $37.9M | Sell |
611,700
-27,000
| -4% | -$1.65M | 0.02% | 616 |
|
|
2016
Q1 | $36.5M | Sell |
638,700
-300,500
| -32% | -$16.7M | 0.02% | 588 |
|
|
2015
Q4 | $55.6M | Buy |
939,200
+178,900
| +24% | +$10.3M | 0.04% | 477 |
|
|
2015
Q3 | $41.4M | Sell |
760,300
-170,400
| -18% | -$11.1M | 0.03% | 537 |
|
|
2015
Q2 | $62.5M | Buy |
930,700
+441,700
| +90% | +$28.8M | 0.04% | 450 |
|
|
2015
Q1 | $28.6M | Buy |
489,000
+312,000
| +176% | +$18.8M | 0.02% | 760 |
|
|
2014
Q4 | $11.6M | Buy |
+177,000
| New | +$11.2M | 0.01% | 1396 |
|
Other funds holding ABBV
VCM
VPM
UBS Group's ABBV Position: Q1 2026 in Review
UBS Group increased its AbbVie (ABBV) stake by 33% in Q1 2026, buying an estimated $782M and bringing the position to 14,051,196 shares worth $3.06B. The position accounts for 0.46% of the portfolio, ranked #21.
UBS Group first reported a position in ABBV in Q4 2014 and has held it in 46 quarters since. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- UBS Group held 14,051,196 shares of AbbVie worth $3.06B as of Q1 2026.
- UBS Group bought 3,524,276 AbbVie shares in Q1 2026, an estimated $782M.
- AbbVie made up 0.46% of UBS Group's portfolio in Q1 2026, its #21 holding.
- UBS Group first reported a position in AbbVie in Q4 2014 and has held it in 46 quarters since.
- 4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.